Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Incyte Corporation stock | $83.33

Learn how to easily invest in Incyte Corporation stock.

Incyte Corporation
NASDAQ: INCY - USD
BIOTECHNOLOGY
$77.35
-$0.05 (-0.06%)

Incyte Corporation is a biotechnology business based in the US. Incyte Corporation shares (INCY) are listed on the NASDAQ and all prices are listed in US Dollars. Incyte Corporation employs 1,773 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Incyte Corporation

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – INCY – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Incyte Corporation stock price (NASDAQ: INCY)

Use our graph to track the performance of INCY stocks over time.

Incyte Corporation shares at a glance

Information last updated 2021-07-30.
Latest market close$83.33
52-week range$75.52 - $102.61
50-day moving average $82.07
200-day moving average $83.63
Wall St. target price$106.14
PE ratio 35.4883
Dividend yield N/A (0%)
Earnings per share (TTM) $2.18

Buy Incyte Corporation shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Webull
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $3.00 and $300 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
Stocks, ETFs
N/A
$0 per month
Download and sign up with Public.com; approved accounts receive a free stock slice worth up to $70, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
0%
N/A
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Robinhood
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Moomoo
Stocks, Options, ETFs
$0
$0 per year
N/A
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Incyte Corporation stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Incyte Corporation price performance over time

Historical closes compared with the close of $83.33 from 2021-06-04

1 week (2021-07-21) N/A
1 month (2021-07-01) -0.82%
3 months (2021-04-30) -2.40%
6 months (2021-01-28) N/A
1 year (2020-07-28) N/A
2 years (2019-07-28) N/A
3 years (2018-07-28) N/A
5 years (2016-07-28) N/A

Is Incyte Corporation under- or over-valued?

Valuing Incyte Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Incyte Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Incyte Corporation's P/E ratio

Incyte Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 35x. In other words, Incyte Corporation shares trade at around 35x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Incyte Corporation's PEG ratio

Incyte Corporation's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.9078. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Incyte Corporation's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Incyte Corporation's EBITDA

Incyte Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $575 million.

The EBITDA is a measure of a Incyte Corporation's overall financial performance and is widely used to measure a its profitability.

Incyte Corporation financials

Revenue TTM $2.7 billion
Operating margin TTM 19.25%
Gross profit TTM $276.6 million
Return on assets TTM 10.14%
Return on equity TTM 20.51%
Profit margin 17.7%
Book value $12.41
Market capitalisation $17 billion

TTM: trailing 12 months

Shorting Incyte Corporation shares

There are currently 5.9 million Incyte Corporation shares held short by investors – that's known as Incyte Corporation's "short interest". This figure is 5.5% up from 5.6 million last month.

There are a few different ways that this level of interest in shorting Incyte Corporation shares can be evaluated.

Incyte Corporation's "short interest ratio" (SIR)

Incyte Corporation's "short interest ratio" (SIR) is the quantity of Incyte Corporation shares currently shorted divided by the average quantity of Incyte Corporation shares traded daily (recently around 1.3 million). Incyte Corporation's SIR currently stands at 4.63. In other words for every 100,000 Incyte Corporation shares traded daily on the market, roughly 4630 shares are currently held short.

However Incyte Corporation's short interest can also be evaluated against the total number of Incyte Corporation shares, or, against the total number of tradable Incyte Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Incyte Corporation's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Incyte Corporation shares in existence, roughly 30 shares are currently held short) or 0.0315% of the tradable shares (for every 100,000 tradable Incyte Corporation shares, roughly 32 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Incyte Corporation.

Find out more about how you can short Incyte Corporation stock.

Incyte Corporation's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Incyte Corporation.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

Incyte Corporation's total ESG risk score

Total ESG risk: 29.4

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Incyte Corporation's overall score of 29.4 (as at 12/31/2018) is nothing to write home about – landing it in it in the 48th percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Incyte Corporation is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

Incyte Corporation's environmental score

Environmental score: 7.61/100

Incyte Corporation's environmental score of 7.61 puts it squarely in the 8th percentile of companies rated in the same sector. This could suggest that Incyte Corporation is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Incyte Corporation's social score

Social score: 24.73/100

Incyte Corporation's social score of 24.73 puts it squarely in the 8th percentile of companies rated in the same sector. This could suggest that Incyte Corporation is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Incyte Corporation's governance score

Governance score: 12.56/100

Incyte Corporation's governance score puts it squarely in the 8th percentile of companies rated in the same sector. That could suggest that Incyte Corporation is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Incyte Corporation's controversy score

Controversy score: 1/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. Incyte Corporation scored a 1 out of 5 for controversy – the highest score possible, reflecting that Incyte Corporation has managed to keep its nose clean.

Environmental, social, and governance (ESG) summary

Incyte Corporation was last rated for ESG on: 2019-01-01.

Total ESG score 29.4
Total ESG percentile 47.86
Environmental score 7.61
Environmental score percentile 8
Social score 24.73
Social score percentile 8
Governance score 12.56
Governance score percentile 8
Level of controversy 1

Incyte Corporation share dividends

We're not expecting Incyte Corporation to pay a dividend over the next 12 months.

Have Incyte Corporation's shares ever split?

Incyte Corporation's shares were split on a 2:1 basis on 31 August 2000. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Incyte Corporation shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Incyte Corporation shares which in turn could have impacted Incyte Corporation's share price.

Incyte Corporation share price volatility

Over the last 12 months, Incyte Corporation's shares have ranged in value from as little as $75.52 up to $102.605. A popular way to gauge a stock's volatility is its "beta".

INCY.US volatility(beta: 0.8)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Incyte Corporation's is 0.7971. This would suggest that Incyte Corporation's shares are less volatile than average (for this exchange).

Incyte Corporation overview

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor for the treatment of adults; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a drug that is in Phase III clinical trial for steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase III clinical trial to treat naïve chronic GVHD; and pemigatinib that is in Phase II clinical trial for treating bladder cancer, cholangiocarcinoma, 8p11 myeloproliferative syndrome, and Tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, the company develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd. ; Eli Lilly and Company; Agenus Inc.

Stocks similar to Incyte Corporation

Frequently asked questions

What percentage of Incyte Corporation is owned by insiders or institutions?
Currently 1.46% of Incyte Corporation shares are held by insiders and 94.017% by institutions.
How many people work for Incyte Corporation?
Latest data suggests 1,773 work at Incyte Corporation.
When does the fiscal year end for Incyte Corporation?
Incyte Corporation's fiscal year ends in December.
Where is Incyte Corporation based?
Incyte Corporation's address is: 1801 Augustine Cut-Off, Wilmington, DE, United States, 19803
What is Incyte Corporation's ISIN number?
Incyte Corporation's international securities identification number is: US45337C1027
What is Incyte Corporation's CUSIP number?
Incyte Corporation's Committee on Uniform Securities Identification Procedures number is: 45337C102

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site